Biomea Fusion Plans Public Offering of Securities

Biomea Fusion Announces Proposed Stock Offering

Redwood City, California, June 17, 2025 – Biomea Fusion, Inc. (NASDAQ: BMEA), a company focused on diabetes and obesity treatments, has revealed plans for a stock offering. The offering comprises common stock, accompanied by warrants for additional stock purchases. They’re also looking to provide underwriters with a 30-day option to purchase up to 15% of the shares. All shares in this offering will be issued by Biomea.

Now, of course, there are some uncertainties involved. The success and exact size of this offering are not guaranteed, and the company can’t specify when it might actually happen.

The company aims to finalize the offering around June 20, 2025, provided that all standard conditions are met.

Jefferies is serving as the main book-running manager for this proposed initiative.

Details regarding common stock and warrants can be found in a filing with the U.S. Securities and Exchange Commission (SEC). If you’re interested, additional information may come through prospectus supplements, accessible through Jefferies LLC.

This announcement does not serve as an offer to sell or a solicitation to buy any of these securities where it may not be legal under specific state laws.

About Biomea Fusion: the company focuses on developing oral small molecules to treat diabetes and obesity.

Forward-looking statements indicate that the timing and scale of this offering depend on various market conditions and internal assessments. Risks and uncertainties surrounding this initiative, along with other potential risks, are highlighted in Biomea’s recent Annual Report and subsequent filings. The statements provided here express Biomea’s current views and are not obligated to be updated except as required by law.